Study guide
6.2 Adjuvant Analgesics
Certified Hospice and Palliative Nurse CHPN
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise
2 Chapter 2: Assessment, Goals, and Care Planning
2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions
3 Chapter 3: Life-Limiting Disease Progression I
3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression
4 Chapter 4: Disease Progression II and Imminent Death
4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death
5 Chapter 5: Pain Assessment
5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience
6 Chapter 6: Pharmacologic Pain Management
6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes
7 Chapter 7: Nonpharmacologic Pain and Opioid Safety
7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation
8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms
8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions
9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms
9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms
10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms
10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden
11 Chapter 11: Advance Care Planning, Benefits, and Safety
11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional
12 Chapter 12: Communication, Culture, and Psychosocial Support
12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation
13 Chapter 13: Caregiver Education and Medication Management
13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services
14 Chapter 14: Grief, Death, and End-of-Life Ethics
14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life
15 Chapter 15: Medicare Hospice Compliance and National Standards
15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines
16 Chapter 16: Legal, Professional Practice, Quality, and Policy
16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends
6.2 Adjuvant Analgesics
Key Takeaways Explain This Topic AI
Adjuvant analgesics treat a mechanism (neuropathic, inflammatory, spastic, capsular, or central edema); they are not a substitute for opioids when cancer pain is severe.
Gabapentin and pregabalin are first-line neuropathic adjuvants and must be renally dosed; start low in frail older adults.
Duloxetine and venlafaxine are SNRI adjuvants for neuropathic pain; amitriptyline and even nortriptyline carry anticholinergic burden that is dangerous in the elderly.
Dexamethasone is the high-yield steroid for bone pain, hepatic capsule stretch, brain metastases, and spinal cord compression, used with opioids rather than instead of them.
Topical lidocaine is for focal neuropathic allodynia; ketamine is refractory specialist use; baclofen is for upper-motor-neuron spasm and must not be stopped abruptly.
Last updated: August 2026
6.2 Adjuvant Analgesics
An adjuvant analgesic (co-analgesic) is a drug whose primary label may not be pain, but which reduces a specific pain mechanism . On the CHPN exam, adjuvants are tested as risk/benefit add-ons . The stem that fails candidates is the one where severe nociceptive cancer pain is treated with gabapentin instead of an opioid. Adjuvants do not replace morphine for a 9/10 pancreatic mass. They sit on top of an appropriate opioid when the mechanism calls for them.
Think in mechanisms, not in a shopping list:
Damaged nerve (burning, shooting, allodynia) → gabapentinoid, SNRI, or cautious TCA, plus topical lidocaine if the area is focal.
Prostaglandin-rich bone or tissue inflammation → NSAID if safe, or dexamethasone.
Peritumoral edema (brain metastases, cord compression, liver-capsule stretch) → dexamethasone.
Upper-motor-neuron spasm → baclofen.
Opioid-refractory neuropathic or mixed pain after specialist review → ketamine.
Gabapentinoids: neuropathic pain, renal dosing
Gabapentin and pregabalin bind the alpha-2-delta subunit of voltage-gated calcium channels and reduce excitatory neurotransmitter release in damaged nerves. They are first-line oral adjuvants for chemotherapy-induced peripheral neuropathy, malignant plexopathy, post-herpetic neuralgia, and mixed neuropathic cancer pain.
Both are cleared by the kidney. That is the CHPN safety fact. A dying patient with a creatinine of 2.4 mg/dL who is started on gabapentin 300 mg three times daily will become sedated, ataxic, and myoclonic, and the team will blame the opioid. Renally dose from the start. In frail older adults, start low (often 100 mg at bedtime for gabapentin, or 25–50 mg of pregabalin) and titrate to effect every few days, not every few hours.
- Estimated CrCl Gabapentin teaching dose Pregabalin teaching dose
- Greater than 60 mL/min 100–300 mg at night, titrate toward divided daily doses 25–75 mg/day, titrate
- 30–59 mL/min Reduce total daily milligrams; often twice daily Reduce; often twice daily
- 15–29 mL/min Once daily or smaller divided doses Once daily
- Less than 15 mL/min or dialysis Very small daily or post-dialysis supplemental dose Specialist renal dosing
Pregabalin has more linear oral absorption than gabapentin, so milligram titration is more predictable, but it is still a renal drug. Neither gabapentinoid is an opioid. Neither treats a pathologic femoral fracture as monotherapy.
SNRIs and tricyclics
Duloxetine and venlafaxine are serotonin/norepinephrine reuptake inhibitors with evidence in neuropathic pain, including diabetic neuropathy and, for duloxetine, chemotherapy-induced peripheral neuropathy. They can also treat comorbid depression, which is not a reason to skip the pain indication. Watch for hyponatremia, nausea, and — with venlafaxine — blood-pressure rise and withdrawal if stopped abruptly. Do not combine casually with tramadol (Section 6.1) or other serotonergic agents.
Amitriptyline and nortriptyline are tricyclic antidepressants used at lower-than-antidepressant doses for neuropathic pain. They are anticholinergic . In an older hospice patient that means constipation on top of opioid constipation, urinary retention, dry mouth, blurred vision, tachycardia, and delirium. Amitriptyline is the worst of the two. Nortriptyline (a secondary amine) is somewhat less anticholinergic and is the TCA more often still considered, but it is still used with caution in the elderly, not as a default sleep aid that happens to treat pain. Cardiac conduction disease is another reason to pick an SNRI or gabapentinoid instead.
Dexamethasone: bone, liver capsule, brain metastases, cord compression
Dexamethasone is the high-yield corticosteroid on this exam. It reduces peritumoral edema and inflammatory cytokine signaling. Four hospice pictures should make you reach for it in addition to an opioid, not instead of one:
Painful bone metastases , especially with inflammatory night pain, when an NSAID is unsafe or insufficient.
Hepatic capsule stretch from bulky liver metastases — sharp right-upper-quadrant pain worse with inspiration or position.
Brain metastases with headache, nausea, or focal signs from vasogenic edema.
Malignant spinal cord compression — new back pain, leg weakness, bowel/bladder change — where dexamethasone is disease-modifying while radiation or surgery is arranged.
Typical CHPN-level teaching ranges (always follow the agency and the prescriber): about 4–8 mg daily for bone or liver-capsule pain; often 8–16 mg daily (sometimes higher initially) for brain metastases or cord compression. Give once daily in the morning when possible to limit insomnia. Monitor hyperglycemia, oral thrush, agitation or steroid psychosis, and proximal myopathy if use is prolonged. In the last days of life, the benefit-to-burden ratio is still often favorable for cord compression and capsular pain.
NSAIDs as adjuvants, topical lidocaine, ketamine, baclofen
NSAIDs as adjuvants are the same drugs as in 6.1, now named correctly as co-analgesics for bone and inflammatory pain sitting beside an opioid. The GI, renal, and platelet cautions do not disappear because the opioid is on board. Combining an NSAID with dexamethasone raises gastrointestinal bleed risk; that combination is a classic question trap.
Topical lidocaine (5% patch or gel on intact skin) is for focal neuropathic allodynia — a strip of chest-wall pain after thoracotomy or a dermatomal band after herpes zoster. Systemic absorption is low when used as labeled. It will not treat visceral pancreatic pain or diffuse bone pain.
Ketamine is an NMDA-receptor antagonist used for refractory neuropathic or mixed pain after ordinary opioids and adjuvants have failed. It is specialist territory (palliative medicine, pain, or anesthesia). Adverse effects include dysphoria, hallucinations, hypertension, and tachycardia. The floor nurse does not start ketamine from a standing hospice admission kit.
Baclofen is a GABA-B agonist for spasticity from upper-motor-neuron disease (multiple sclerosis, ALS, spinal metastases). It is not a general cancer-pain opioid substitute. Abrupt withdrawal can cause seizures, rebound rigidity, and hallucinations , so a patient who can no longer swallow needs a taper or a route change, not a sudden stop. Baclofen is renally cleared; reduce the dose when GFR falls.
Worked adjuvant example
A 68-year-old with metastatic breast cancer has 8/10 dull chest-wall pain from rib metastases and a burning band of allodynia in the same dermatome after zoster. Creatinine is 1.8 mg/dL (estimated CrCl about 35 mL/min). She already takes morphine ER 15 mg every 12 hours with little relief of the dull pain, and she is not on an SSRI.
Do not stop the opioid. Increase or titrate the morphine for the nociceptive bone pain (6.3) and add mechanism-specific adjuvants: dexamethasone (or an NSAID if platelets and GI risk allow) for bone inflammation, topical lidocaine on the allodynic band, and a renally reduced gabapentin start (not 300 mg three times daily). Duloxetine could be a neuropathic add-on later if the gabapentinoid is not tolerated. Ketamine is not the opening move. Gabapentin alone, with the morphine held, is the wrong architecture.
Adjuvants answer why it hurts that way . Opioids still answer how much it hurts when cancer pain is severe.